SAN FRANCISCO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the Company will be participating in the upcoming Baird 2023 Global Healthcare Conference and the Morgan Stanley 21st Annual Global Healthcare Conference.
iRhythm’s management is scheduled to present at Baird’s 2023 Global Healthcare Conference on Tuesday, September 12, at 9:05 am Eastern Time and at the Morgan Stanley Global Healthcare Conference on Wednesday, September 13, at 1:35 pm Eastern Time. Those interested in listening to the presentation may do so by accessing the live and archived webcast of the events, which will be available on the investors section of the Company’s website at investors.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.
Investor Relations Contact
Stephanie Zhadkevich
(919) 452-5430
This email address is being protected from spambots. You need JavaScript enabled to view it.
iRhythm Media Contact:
Saige Smith
(262) 289-7065
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$99.90 |
| Daily Change: | -0.05 -0.05 |
| Daily Volume: | 251,818 |
| Market Cap: | US$3.130B |
February 20, 2025 December 30, 2024 October 30, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
